Navigation Links
SUMO protein guides chromatin remodeler to suppress genes
Date:4/27/2009

BOSTON (April 27, 2009) In an in vitro study, led by Grace Gill, PhD, Tufts University School of Medicine, researchers discovered how a protein called SUMO (Small Ubiquitin-related Modifier) guides an enzyme complex that alters the structure of chromatin to regulate expression of genes. Chromatin is a compacted mass of DNA and protein that make up chromosomes. The interaction between SUMO and the enzyme complex is of interest in the study of cancer and neurodegenerative diseases such as Alzheimer's, where aberrant gene expression and altered SUMO function are thought to be indicative of disease.

The protein called SUMO is known to chemically modify other proteins, called transcription factors, which in turn enables the meticulous regulation of genes. Gene regulation is a fundamental biological process that allows necessary genes to be turned on or off in specific cell types.

The researchers found that SUMO interacts with an enzyme complex (LSD1/CoREST/HDAC) that alters chromatin structure to regulate genes within cells. The researchers found that the interaction between SUMO and this enzyme complex is responsible for preventing aberrant expression. Aberrant gene expression is a common feature of cancer and other disorders and altered SUMO processes might contribute to neurodegeneration.

"We've only known for about 10 years that SUMO chemically modifies proteins. We have a good understanding of how SUMO modifies other proteins, but the actual mechanism of how this modification alters cell function is not well known. Our study uncovers a fundamental aspect of how SUMO works, which has implications for many diseases. Until now, SUMO and LSD1/CoREST/HDAC have not been studied together; we've found out how they work together to turn off certain genes," says Gill.

The Gill Lab is continuing to investigate SUMO-dependent cell activity to delineate the complex genetic mechanisms that support gene regulation.

First author Jian Ouyang, PhD, is a postdoctoral associate in Gill's lab, formerly in the department of pathology at Harvard Medical School.

Senior author Grace Gill, PhD, is an associate professor at Tufts University School of Medicine and a member of the genetics and cell, molecular and developmental biology program faculties at the Sackler School of Graduate Biomedical Sciences at Tufts, formerly in the department of pathology at Harvard Medical School.


'/>"/>

Contact: Siobhan E. Gallagher
617-636-6586
Tufts University, Health Sciences
Source:Eurekalert

Related biology news :

1. New study reveals the protein that makes phosphate chains in yeast
2. Autopilot guides proteins in brain
3. New data on the breakdown of the KRas protein
4. HIV dearms protective protein in cells
5. UC Riverside biochemist to study how crops can increase protein production
6. Cloud computing brings cost of protein research down to Earth
7. Penn biologists discover how silent mutations influence protein production
8. New method for detection of phosphoproteins reveals regulator of melanoma invasion
9. New therapeutic strategy could target toxic protein in most patients with Huntingtons disease
10. ISU researcher identifies protein that concentrates carbon dioxide in algae
11. Orientation of antenna protein in photosynthetic bacteria described
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/14/2017)... 14, 2017  Wake Forest Baptist Medical Center today ... chief executive officer (CEO). Freischlag joins the medical center ... McConnell , M.D., who last year announced that he ... Center, after leading it since 2008.   ... Wake Forest Baptist,s academic health system, which includes Wake ...
(Date:2/8/2017)... 8, 2017 About Voice Recognition Biometrics Voice ... it against a stored voiceprint template. Acoustic features ... and tone are compared to distinguish between individual ... as most PCs already have a microphone and ... recognition biometrics are most likely to be deployed ...
(Date:2/7/2017)... 2017   MedNet Solutions , an innovative SaaS-based ... clinical research, is pleased to announce that the latest ... highly flexible and award winning eClinical solution, is now ... is a proven Software-as-a-Service (SaaS) clinical research technology ... but also delivers an entire suite of eClinical tools ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... 2017 Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, ... clinical-stage oncology and dermatology biopharmaceutical company, today is ... in its previously announced rights offering of up ... common stock and Series C Convertible Preferred Stock ... As previously announced, the rights ...
(Date:2/24/2017)... , Feb. 24, 2017 Symic Bio, a ... a new category of therapeutics, announced today the completion ... in peripheral artery disease. The trial will evaluate the ... therapeutic, in the reduction of restenosis following angioplasty. ... development milestone for SB-030," said Nathan Bachtell , ...
(Date:2/24/2017)... China Cord Blood Corporation (NYSE: CO ) ... blood collection, laboratory testing, hematopoietic stem cell processing and ... results for the third quarter and first nine months ... Third Quarter of Fiscal 2017 Highlights ... increased by 18.6% to RMB200.9 million ($28.9 million). ...
(Date:2/24/2017)... 2017 China Biologic Products, Inc. (NASDAQ: CBPO) ("China ... company in China, today announced its financial results for the ... Fourth Quarter 2016 Financial Highlights Total ... in RMB terms, or increased by 13.6% in USD terms ... of 2015. Gross profit increased by 13.3% ...
Breaking Biology Technology: